Myriad Genetics to Present Seven Studies at the 2017 American Society of Clinical Oncology Annual Meeting

Presentations Highlight Continued Advancements in Hereditary Cancer Panel Testing

Print
| Source: Myriad Genetics, Inc.

SALT LAKE CITY, May 18, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it will present results from seven studies at the 2017 American Society of Clinical Oncology (ASCO) annual meeting to be held June 2 to 6, 2016 in Chicago, Ill.  Abstracts of the Company's presentations are currently available at: abstracts.asco.org

“We look forward to presenting important new research at ASCO in collaboration with our academic partners, advancing personalized medicine in the field of oncology,” said Johnathan Lancaster, M.D., Ph.D., chief medical officer, Myriad Genetic Laboratories. “Our presentations will highlight advances in companion diagnostics, hereditary cancer risk assessment, and prediction of oncologic outcomes, all of which are designed to meaningfully improve clinical care for patients.”

A list of Myriad presentations at ASCO 2017 is below.  Follow Myriad on Twitter via @MyriadGenetics and stay informed about symposium news and updates by using the hashtag #ASCO17.

 

Title
 

Author
Poster/Abstract Number 

Day/Time
Myriad Product
 
Podium Presentation
    
Evaluation of BRCA1/2 and homologous
recombination defects in ovarian cancer and
impact on clinical outcomes
Melinda YatesAbstract 5511Monday,
June 5,
2017: 8:00-
9:30 a.m.
CDT.
Room
E450ab

 
myChoice
HRD
Poster Discussion    
Quantifying Gender Ascertainment Bias in
Hereditary Cancer Testing

 
Anthony ChenAbstract 6516
Poster Board
338
Monday,
June 5,
2017: 1:15-
4:45 p.m.
and 4:45-
6:00 p.m.
CDT.
Myriad
myRisk
Poster Presentations     
Expanded Yield of Multiplex Panel Testing in
Fully Accrued Prospective Trial

 

 

 

Performance of Mutation Risk Prediction
Models in a Racially Diverse Multi-Gene Panel
Testing Cohort

 
Gregory IdosAbstract 1525
Poster Board
183

 

 

Abstract 1523
Poster Board
181

 
Monday,
June 5,
2017: 1:15-
4:45 p.m.
CDT.
Myriad
myRisk
Development and Validation of a Residual Risk
Score to Predict Breast Cancer Risk in
Unaffected Women Negative for Mutations on a
Multi-Gene Hereditary Cancer Panel

 
Elisha HughesAbstract 1579
Poster Board
237
Monday,
June 5,
2017: 1:15-
4:45 p.m.
CDT.
Myriad
myRisk
Safety of Multiplex Gene Testing for Inherited
Cancer Risk in a Fully Accrued Prospective
Trial
Allison KurianAbstract 1576
Poster Board
234
Monday,
June 5,
2017: 1:15-
4:45 p.m.
CDT.

 
Myriad
myRisk
Multi-Gene Hereditary Cancer Testing among
Men with Breast Cancer
Krystal BrownAbstract 1532
Poster Board
190
Monday,
June 5,
2017: 1:15-
4:45 p.m. CDT.
Myriad
myRisk
     

About Myriad myRisk® Hereditary Cancer

The Myriad myRisk Hereditary Cancer test uses an extensive number of sophisticated technologies and proprietary algorithms in an 850 step laboratory process to evaluate 25 clinically significant genes associated with eight hereditary cancer sites including: breast, colon, ovarian, endometrial, pancreatic, prostate and gastric cancers and melanoma.  For more information visit: https://www.myriad.com/products-services/hereditary-cancers/myrisk-hereditary-cancer/.

About myChoice® HRD

Myriad's myChoice HRD is the first homologous recombination deficiency test that can detect when a tumor has lost the ability to repair double-stranded DNA breaks, resulting in increased susceptibility to DNA-damaging drugs such as platinum drugs or PARP inhibitors. High myChoice HRD scores reflective of DNA repair deficiencies are prevalent in all breast cancer subtypes, ovarian and most other major cancers.  In previously published data, Myriad showed that the myChoice HRD test predicted drug response to platinum therapy in certain patients with triple-negative breast and ovarian cancers.  It is estimated that 1.8 million people in the United States and Europe who are diagnosed with cancers annually may be candidates for treatment with DNA-damaging agents.

About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics.  Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs.  Myriad is focused on three strategic imperatives:  transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.  For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor Statement       
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to data being presented at the at the 2017 American Society of Clinical Oncology Annual Meeting being held June 2-6, 2017 in Chicago, Ill.; and the Company's strategic directives under the caption "About Myriad Genetics."  These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described or implied in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing product portfolio to our new tests; risks related to changes in the governmental or private insurers' reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire, including but not limited to our acquisition of Assurex, Sividon and the Clinic; risks related to our projections about the potential market opportunity for our products; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements;  the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our Annual report on Form 10-K for the fiscal year ended June 30, 2016, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.

Media Contact:         
Ron Rogers 
(801) 584-3065                 
rrogers@myriad.com           

Investor Contact:
Scott Gleason
(801) 584-1143
sgleason@myriad.com                                    

Jared Maxwell
(801) 505-5027
jmaxwell@myriad.com